Sanofi reported third quarter 2026 sales of €14,444 million and net income of €3,021 million, and raised full year 2026 ...

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on ...

Nov 3 (Reuters) - Nurix Therapeutics said on Tuesday that Sanofi has decided to discontinue development of an experimental ...

By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday it was prepared to pursue larger deals as ...

Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...

Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is ...

Sanofi has predicted that Dupixent will receive “the majority of the benefit” from the direct-to-consumer (DTC) marketing ca ...

Sanofi reported US sales in the second quarter were €4.751 billion and increased by 19.8% CER. Solid performance by Dupixent ...

With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...

Sanofi ( SNY) raised its full-year 2026 guidance after reporting stronger-than-expected third-quarter results, supported by ...

Sanofi has a great financial position. The long-term debt/equity ratio is 0.2, while the interest coverage ratio is 11. See ...

Sanofi Vaccines US, based in Swiftwater, Pennsylvania, has been added as an awardee to an existing Defense Logistics Agency ...